About this trial
Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer, and one of the most common cancers worldwide. The majority of CSCCs are easily removed by surgery and have excellent prognosis. However, a small subset has poor outcomes, including secondary spread in the body (metastasis) and death.
The investigators will look at existing CSCC in people from two UK dermatology centres. The investigators will then evaluate the accuracy of current staging systems in predicting risk of poor outcomes in people. The investigators hope that this project will improve the management of patients with CSCC by validating the predictive power of currently available histological staging classifications for cSCC. In the second stage of the study, The investigators will see whether better prediction tools can be found.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Over 18 years old with diagnosis of CSCC
Disqualifiers
Patients who decline for their data to be used for research purposes
Trial population
Patients treated at two tertiary Dermatology centers
Trial design
Cohort
Retrospective
Treatments tested in this trial
This is not an interventional study
Other interventionThis is not an interventional study
Treatment groups
Trial outcomes
Primary outcomes
Recurrence or metastasis
Proportion of patients developing cutaneous squamous cell carcinoma locoregional recurrence, nodal or distant metastases
Sponsors and contacts
Click on the lead sponsor to view all of their trials.